Trial Search Results

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy surgery is a procedure that removes a smaller number of lymph nodes from your neck because it uses an imaging agent to see which lymph nodes are most likely to have cancer. Standard neck dissection, such as elective neck dissection, removes many of the lymph nodes in your neck. Using sentinel lymph node biopsy surgery may work better in treating patients with early-stage oral cavity cancer compared to standard elective neck dissection.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

NRG Oncology

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):


  • Procedure: Computed Tomography (CT)
  • Drug: Imaging Agent
  • Procedure: Neck Dissection
  • Procedure: Planar Imaging
  • Procedure: Sentinel Lymph Node Biopsy
  • Procedure: Single Photon Emission Computed Tomography


Phase 2/Phase 3


Inclusion Criteria:


   - Pathologically (histologically or cytologically) proven diagnosis of squamous cell
   carcinoma of the oral cavity, including the oral (mobile) tongue, floor of mouth
   (FOM), mucosal lip, buccal mucosa, lower alveolar ridge, upper alveolar ridge,
   retromolar gingiva (retromolar trigone; RMT), or hard palate prior to registration

   - Appropriate stage for study entry (T1-2N0M0; American Joint Committee on Cancer [AJCC]
   8th edition [ed.]) based on the following diagnostic workup:

      - History/physical examination within 42 days prior to registration

      - Imaging of head and neck within 42 days prior to registration

         - PET/CT scan or contrast neck CT scan, or gadolinium-enhanced neck magnetic
         resonance imaging (MRI) or lateral and central neck ultrasound; CT portion
         of the PET/CT must be of diagnostic quality

         - Chest imaging with either a chest x-ray, CT chest scan (with or without
         contrast) or PET/CT (with or without contrast) within 42 days prior to

   - Surgical assessment within 42 days prior to registration. Patient must be a candidate
   for surgical intervention with sentinel lymph node (SLN) biopsy and potential
   completion neck dissection (CND) or elective neck dissection (END)

      - Surgical resection of the primary tumor will occur through a transoral approach
      with anticipation of resection free margins

   - Zubrod performance status 0-2 within 42 days prior to registration

   - For women of child-bearing potential, negative serum or urine pregnancy test within 42
   days prior to registration

   - The patient or a legally authorized representative must provide study-specific
   informed consent prior to study entry

   - Only English-speaking patients (able to read and understand English) are eligible to
   participate as the mandatory patient reported NDII tool is only available in this


   - FDG PET/CT required prior to step 2. Note: FDG PET/CT done prior to step 1 can be
   submitted for central review. However, if the FDG PET/CT is not of diagnostic quality,
   then FDG PET/CT will have to be repeated prior to Step 2 registration

      - PET/CT node negative patients, determined by central read, will proceed to

      - PET/CT positive patients will go off study, but will be entered in a registry and
      data will be collected to record the pathological outcome of neck nodes for
      diagnostic imaging assessment and future clinical trial development

         - NOTE: All FDG PET/CT scans must be performed on an American College of
         Radiology (ACR) accredited scanner (or similar accrediting organization)

Exclusion Criteria:


   - Definitive clinical or radiologic evidence of regional (cervical) and/or distant
   metastatic disease

   - Prior non-head and neck invasive malignancy (except non-melanomatous skin cancer,
   including effectively treated basal cell or squamous cell skin cancer, or carcinoma in
   situ of the breast or cervix) unless disease free for ≥ 2 years

   - Diagnosis of head and neck squamous cell carcinoma (SCC) in the oropharynx,
   nasopharynx, hypopharynx, and larynx

   - Unable or unwilling to complete NDII (baseline only)

   - Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a
   different cancer is allowable

   - Prior radiotherapy to the region of the study cancer that would result in overlap of
   radiation therapy fields

   - Patient with severe, active co-morbidity that would preclude an elective or completion
   neck dissection

   - Pregnancy and breast-feeding mothers

   - Incomplete resection of oral cavity lesion with a positive margin; however, an
   excisional biopsy is permitted

   - Prior surgery involving the lateral neck, including neck dissection or gross injury to
   the neck that would preclude surgical dissection for this trial. Prior thyroid and
   central neck surgery is permissible; biopsy is permitted. Note: Borderline suspicious
   nodes that are ≥ 1 cm with radiographic finding suggestive of NOT malignant should be
   biopsied using ultrasound-guided (U/S-guided) fine-needle aspiration (FNA) biopsy

   - Underlying or documented history of hematologic malignancy (e.g., chronic lymphocytic
   leukemia [CLL]) or other active disease capable of causing lymphadenopathy
   (sarcoidosis or untreated mycobacterial infection)

   - Actively receiving systemic cytotoxic chemotherapy, immunosuppressive, anti-monocyte
   or immunomodulatory therapy

   - Currently participating in another investigational therapeutic trial

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Nikita Bedi